{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:00:36Z","timestamp":1783602036523,"version":"3.55.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017596","name":"Natural Science Basic Research Program of Shaanxi Province","doi-asserted-by":"publisher","award":["2023-JC-QN-0877"],"award-info":[{"award-number":["2023-JC-QN-0877"]}],"id":[{"id":"10.13039\/501100017596","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017614","name":"Xi'an Medical University","doi-asserted-by":"publisher","award":["2023BS10"],"award-info":[{"award-number":["2023BS10"]}],"id":[{"id":"10.13039\/501100017614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22407109"],"award-info":[{"award-number":["22407109"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304454"],"award-info":[{"award-number":["82304454"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejmech.2025.117852","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T11:08:33Z","timestamp":1749467313000},"page":"117852","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Design, synthesis, and biological evaluation of novel PI3K\u03b4\/HDAC6 dual inhibitors for the treatment of non-Hodgkin's lymphoma"],"prefix":"10.1016","volume":"296","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0294-8788","authenticated-orcid":false,"given":"Yueqi","family":"Zuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingchun","family":"Gou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10229","key":"10.1016\/j.ejmech.2025.117852_bib1","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0140-6736(20)30164-1","article-title":"Small molecules, big impact: 20 years of targeted therapy in oncology","volume":"395","author":"Bedard","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejmech.2025.117852_bib2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrc2559","article-title":"Targeting cancer with small molecule kinase inhibitors","volume":"9","author":"Zhang","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.ejmech.2025.117852_bib3","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1158\/2159-8290.CD-24-0296","article-title":"The epigenetic hallmarks of cancer","volume":"14","author":"Esteller","year":"2024","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117852_bib4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: from mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.ejmech.2025.117852_bib5","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1158\/2159-8290.CD-11-0249","article-title":"PI3K\u03b4 inhibitors in cancer: Rationale and serendipity merge in the clinic","volume":"1","author":"Fruman","year":"2011","journal-title":"Cancer Discov."},{"issue":"10","key":"10.1016\/j.ejmech.2025.117852_bib6","doi-asserted-by":"crossref","first-page":"4815","DOI":"10.1021\/acs.jmedchem.8b01492","article-title":"Class 1 PI3K clinical candidates and recent inhibitor design strategies: a medicinal chemistry perspective","volume":"62","author":"Garces","year":"2019","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117852_bib7","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117852_bib8","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1056\/NEJMe1400055","article-title":"Idelalisib--a PI3Kdelta inhibitor for B-cell cancers","volume":"370","author":"Fruman","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117852_bib9","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117852_bib10","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ejmech.2025.117852_bib11","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood-2017-05-786566","article-title":"Duvelisib, a novel oral dual inhibitor of PI3Kdelta, gamma, is clinically active in advanced hematologic malignancies","volume":"131","author":"Flinn","year":"2018","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.ejmech.2025.117852_bib12","doi-asserted-by":"crossref","first-page":"16033","DOI":"10.1021\/acs.jmedchem.2c01070","article-title":"Targeting the PI3K\/AKT\/mTOR signaling pathway in the treatment of human diseases: current status, trends, and solutions","volume":"65","author":"Huang","year":"2022","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2025.117852_bib13","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/1078-0432.CCR-22-2939","article-title":"The oral PI3K\u03b4 inhibitor linperlisib for the treatment of relapsed and\/or refractory follicular lymphoma: a phase II, single-arm, open-label clinical trial","volume":"29","author":"Wang","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117852_bib14","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1021\/jm501624r","article-title":"Discovery and in vivo evaluation of (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and related PI3Kdelta inhibitors for inflammation and autoimmune disease","volume":"58","author":"Cushing","year":"2015","journal-title":"J. Med. Chem."},{"issue":"7911","key":"10.1016\/j.ejmech.2025.117852_bib15","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41586-022-04685-2","article-title":"Intermittent PI3K\u03b4 inhibition sustains anti-tumour immunity and curbs irAEs","volume":"605","author":"Eschweiler","year":"2022","journal-title":"Nature"},{"issue":"37","key":"10.1016\/j.ejmech.2025.117852_bib16","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1038\/sj.onc.1210599","article-title":"HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention","volume":"26","author":"Yang","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.117852_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117185","article-title":"Synthetic approaches and clinical applications of representative HDAC inhibitors for cancer therapy: a review","volume":"283","author":"Lv","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117852_bib18","article-title":"The role of HDAC6 in cancer","volume":"2011","author":"Aldana-Masangkay","year":"2011","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.ejmech.2025.117852_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105274","article-title":"HDAC6 as privileged target in drug discovery: a perspective","volume":"163","author":"Pulya","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117852_bib20","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"West","year":"2014","journal-title":"J. Clin. Investig."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117852_bib21","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2011-10-387365","article-title":"Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma","volume":"119","author":"Santo","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejmech.2025.117852_bib22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.21037\/cco.2017.01.05","article-title":"The promise of using histone deacetylase inhibitors in combination treatment against breast cancer and other solid tumors","volume":"6","author":"Perera","year":"2017","journal-title":"Chin. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117852_bib23","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2217\/fon.11.2","article-title":"Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer","volume":"7","author":"Thurn","year":"2011","journal-title":"Future Oncol."},{"issue":"7","key":"10.1016\/j.ejmech.2025.117852_bib24","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1021\/acs.jmedchem.8b00189","article-title":"Kinase and histone deacetylase hybrid inhibitors for cancer therapy","volume":"62","author":"Luan","year":"2019","journal-title":"J. Med. Chem."},{"issue":"18","key":"10.1016\/j.ejmech.2025.117852_bib25","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1158\/1078-0432.CCR-14-0034","article-title":"PI3K\/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo","volume":"20","author":"Rahmani","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117852_bib26","first-page":"93","article-title":"Enhanced efficacy of histone deacetylase inhibitor panobinostat combined with dual PI3K\/mTOR inhibitor BEZ235 against glioblastoma","volume":"81","author":"Meng","year":"2019","journal-title":"Nagoya J. Med. Sci."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117852_bib27","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccell.2016.02.011","article-title":"HDAC and PI3K antagonists cooperate to inhibit growth of MYC-driven medulloblastoma","volume":"29","author":"Pei","year":"2016","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.ejmech.2025.117852_bib28","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1002\/med.21972","article-title":"Histone deacetylasebased dual targeted inhibition in multiple myeloma","volume":"43","author":"Ferro","year":"2023","journal-title":"Med. Res. Rev."},{"issue":"17","key":"10.1016\/j.ejmech.2025.117852_bib29","doi-asserted-by":"crossref","first-page":"5044","DOI":"10.1158\/1078-0432.CCR-17-1043","article-title":"Dual inhibition of HDAC and tyrosine kinase signaling pathways with CUDC-907 inhibits thyroid cancer growth and metastases","volume":"23","author":"Kotian","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117852_bib30","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.3324\/haematol.2018.201343","article-title":"Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia","volume":"104","author":"Li","year":"2019","journal-title":"Haematologica (Roma)"},{"issue":"24","key":"10.1016\/j.ejmech.2025.117852_bib31","doi-asserted-by":"crossref","first-page":"6233","DOI":"10.1158\/0008-5472.CAN-21-1547","article-title":"A dual PI3K\/HDAC inhibitor induces immunogenic ferroptosis to potentiate cancer immune checkpoint therapy","volume":"81","author":"Fan","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117852_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128825","article-title":"Bioevaluation of a dual PI3K\/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma","volume":"71","author":"Zhang","year":"2022","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2025.117852_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115915","article-title":"Discovery of benzamide-based PI3K\/HDAC dual inhibitors with marked pro-apoptosis activity in lymphoma cells","volume":"262","author":"Deng","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117852_bib34","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S1470-2045(15)00584-7","article-title":"Safety, tolerability, and preliminary activity of CUDC-907, a frst-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dosage-escalation, phase 1 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117852_bib35","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40264-018-0773-9","article-title":"Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology","volume":"42","author":"Shah","year":"2019","journal-title":"Drug Saf."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117852_bib36","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/blood-2016-02-702761","article-title":"Idelalisib in the management of lymphoma","volume":"128","author":"Cheah","year":"2016","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.ejmech.2025.117852_bib37","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.2217\/fon-2020-0195","article-title":"Copanlisib in the treatment of Non-Hodgkin lymphoma","volume":"16","author":"Narkhede","year":"2020","journal-title":"Future Oncol."},{"issue":"10","key":"10.1016\/j.ejmech.2025.117852_bib38","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/aps.2015.71","article-title":"PI3K isoform-selective inhibitors: next-generation targeted cancer therapies","volume":"36","author":"Wang","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2025.117852_bib39","doi-asserted-by":"crossref","first-page":"971","DOI":"10.3389\/fphar.2020.00971","article-title":"Histone deacetylase 6 as a therapeutic target in B cell-associated hematological malignancies","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"20","key":"10.1016\/j.ejmech.2025.117852_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127479","article-title":"Design, synthesis and structure-activity relationship study of piperazinone-containing thieno[3,2-d]pyrimidine derivatives as new PI3K\u03b4 inhibitors","volume":"30","author":"Wang","year":"2020","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2025.117852_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104344","article-title":"Identification of a potent and selective phosphatidylinositol 3-kinase \u03b4 inhibitor for the treatment of non-hodgkin's lymphoma","volume":"105","author":"Zuo","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.117852_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106622","article-title":"Recent development of selective inhibitors targeting the HDAC6 as anti-cancer drugs: structure, function and design","volume":"138","author":"Peng","year":"2023","journal-title":"Bioorg. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117852_bib43","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s13402-022-00704-6","article-title":"HDAC6: a unique HDAC family member as a cancer target","volume":"45","author":"Kaur","year":"2022","journal-title":"Cell. Oncol."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117852_bib44","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nchembio0310-244b","article-title":"The p110delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors","volume":"6","author":"Berndt","year":"2010","journal-title":"Nat. Chem. Biol."},{"issue":"9","key":"10.1016\/j.ejmech.2025.117852_bib45","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nchembio.2134","article-title":"Histone deacetylase 6 structure and molecular basis of catalysis and inhibition","volume":"12","author":"Hai","year":"2016","journal-title":"Nat. Chem. Biol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425006178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425006178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T14:13:07Z","timestamp":1762265587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425006178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":45,"alternative-id":["S0223523425006178"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117852","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological evaluation of novel PI3K\u03b4\/HDAC6 dual inhibitors for the treatment of non-Hodgkin's lymphoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117852","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117852"}}